FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to T-cell receptors (hereinafter – TCR), which bind to HLA-A*02 complex with a cancer antigen MAGE A4 GVYDGREHTV (SEQ ID NO: 1); it can be used in medicine.
EFFECT: obtained TCR can be part of a hybrid TCR-anti-CD3 molecule containing TCR and an antibody against CD3 for the redirection of T-cells to cells representing antigen MAGE-A4, and they can be used for the effective therapy of MAGE A4-expressing tumors.
45 cl, 11 dwg, 12 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
